Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.72
- Piotroski Score 7.00
- Grade Buy
- Symbol (LIVN)
- Company LivaNova PLC
- Price $51.69
- Changes Percentage (3.28%)
- Change $1.64
- Day Low $49.66
- Day High $51.80
- Year High $64.48
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $68.00
- High Stock Price Target $88.00
- Low Stock Price Target $62.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.60
- Trailing P/E Ratio -88.97
- Forward P/E Ratio -88.97
- P/E Growth -88.97
- Net Income $17.55 M
Income Statement
Quarterly
Annual
Latest News of LIVN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
LivaNova PLC (LIVN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
The CFO discussed the rationale behind the second half of 2024 guidance, focusing on sustainable growth and margin expansion. The decision to pursue CMS coverage for DTD was driven by positive patient...
By Yahoo! Finance | 1 month ago -
Insider Sale: Director Francesco Bianchi Sells 1,500 Shares of LivaNova PLC (LIVN)
LivaNova PLC is a global medical technology company specializing in cardiovascular and neurological treatments. Recent insider transactions, including Director Francesco Bianchi's sell-off, show a tre...
By Yahoo! Finance | 2 months ago -
LivaNova PLC (LIVN) Stock Price, News, Quote & History - Yahoo Finance
LivaNova PLC is a global medical device company specializing in therapeutic solutions. They offer products in Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments, serving vario...
By Yahoo! Finance | 4 months ago
